CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.2978
-0.0180 (-5.70%)
Jun 26, 2025, 3:59 PM EDT
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
374.67M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Elite Pharmaceuticals | 70.00M |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
CytoDyn News
- 2 days ago - CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer - GlobeNewsWire
- 4 weeks ago - A Penny Stock To Watch In Challenging Cancer Space - Benzinga
- 6 weeks ago - CytoDyn Releases ESMO Breast Cancer Meeting Poster - GlobeNewsWire
- 6 weeks ago - CytoDyn highlights potential of lead drug against solid tumors with new data - Seeking Alpha
- 6 weeks ago - CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors - GlobeNewsWire
- 7 weeks ago - CytoDyn appoints Robert Hoffman as CFO - Seeking Alpha
- 7 weeks ago - CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - Benzinga
- 7 weeks ago - CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - GlobeNewsWire